Mohamed Atef El Gammal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed Atef El Gammal has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Amal Abdullah Alrashidi
Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
2 shared publications - Eman H. Yousef
Department of Pharmacology and Biochemistry (Biochemistry), Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt
2 shared publications - Muhammed M. Salahuddin
Department of Pharmacology and Biochemistry (Biochemistry), Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt
2 shared publications A. I. Elberri
Menoufia Univ, Genet Engn & Mol Biol Div, Dept Zool, Fac Sci, Menoufia, Egypt
1 shared publication- Ahmed F. Mohamed
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt
1 shared publication Ahmed G. Abd Elhameed
Pharmacology and Toxicology Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt
1 shared publication
Latest Publications
- Open Access
- 31 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (8) , 1721
Vardenafil Alleviates Doxorubicin-Induced Cardiotoxicity Associated with Restoration of the AMPK/SIRT1 Signaling Pathway
Background: Doxorubicin-induced cardiotoxicity (DIC) is a major limitation of anthracycline chemotherapy and is characterized by oxidative stress, apoptosis, and myocardial remodeling. Dysregulation of AMP-activated protein kinase (AMPK) and its downstream effector sirtuin-1 (SIRT1) has been implicated in the molecular pathogenesis of DIC. Vardenafil (Var), a selective phosphodiesterase-5 inhibitor, has shown cardiovascular benefits; however, its impact on AMPK/SIRT1 signaling during DIC remains unclear. Methods: DIC was induced in rats by cumulative doxorubicin administration. Cardiac function, serum injury biomarkers, oxidative stress indices, histopathological alterations, apoptosis, fibrosis, and molecular markers associated with the AMPK/SIRT1 pathway were evaluated. In addition, molecular docking was performed to assess the potential interaction of Var with AMPK. Results: Var significantly improved cardiac function and reduced serum levels of lactate dehydrogenase, creatine kinase, and blood urea nitrogen. Treatment attenuated myocardial oxidative stress, restored glutathione content, reduced lipid peroxidation, and alleviated histopathological damage. Furthermore, Var suppressed caspase-3 and TGF-β1 expression while enhancing HO-1 levels. Var treatment was associated with restoration of cardiac phosphorylated AMPK (p-AMPK) expression and increased SIRT1, Nrf2, and PPARγ levels in doxorubicin-treated rats, consistent with modulation of an AMPK/SIRT1-associated cytoprotective network. Molecular docking demonstrated favorable interactions between Var and AMPK, providing supportive in silico evidence for the observed molecular findings. Conclusions: These findings demonstrate that Var attenuates doxorubicin-induced cardiotoxicity, and its cardioprotective effects are associated with restoration of the p-AMPK/SIRT1/Nrf2/PPARγ signaling pathway, together with reductions in oxidative stress, apoptosis, and fibrosis. Collectively, these findings suggest that Var attenuates early Dox-induced cardiac injury, potentially through modulation of the AMPK/SIRT1 signaling pathway, warranting further validation in long-term and dose–response studies.
- 31 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (8) , 1721
Open AccessVardenafil Alleviates Doxorubicin-Induced Cardiotoxicity Associated with Restoration of the AMPK/SIRT1 Signaling Pathway
Background: Doxorubicin-induced cardiotoxicity (DIC) is a major limitation of anthracycline chemotherapy and is characterized by oxidative stress, apoptosis, and myocardial remodeling. Dysregulation of AMP-activated protein kinase (AMPK) and its downstream effector sirtuin-1 (SIRT1) has been implicated in the molecular pathogenesis of DIC. Vardenafil (Var), a selective phosphodiesterase-5 inhibitor, has shown cardiovascular benefits; however, its impact on AMPK/SIRT1 signaling during DIC remains unclear. Methods: DIC was induced in rats by cumulative doxorubicin administration. Cardiac function, serum injury biomarkers, oxidative stress indices, histopathological alterations, apoptosis, fibrosis, and molecular markers associated with the AMPK/SIRT1 pathway were evaluated. In addition, molecular docking was performed to assess the potential interaction of Var with AMPK. Results: Var significantly improved cardiac function and reduced serum levels of lactate dehydrogenase, creatine kinase, and blood urea nitrogen. Treatment attenuated myocardial oxidative stress, restored glutathione content, reduced lipid peroxidation, and alleviated histopathological damage. Furthermore, Var suppressed caspase-3 and TGF-β1 expression while enhancing HO-1 levels. Var treatment was associated with restoration of cardiac phosphorylated AMPK (p-AMPK) expression and increased SIRT1, Nrf2, and PPARγ levels in doxorubicin-treated rats, consistent with modulation of an AMPK/SIRT1-associated cytoprotective network. Molecular docking demonstrated favorable interactions between Var and AMPK, providing supportive in silico evidence for the observed molecular findings. Conclusions: These findings demonstrate that Var attenuates doxorubicin-induced cardiotoxicity, and its cardioprotective effects are associated with restoration of the p-AMPK/SIRT1/Nrf2/PPARγ signaling pathway, together with reductions in oxidative stress, apoptosis, and fibrosis. Collectively, these findings suggest that Var attenuates early Dox-induced cardiac injury, potentially through modulation of the AMPK/SIRT1 signaling pathway, warranting further validation in long-term and dose–response studies.
- 5 November 2024
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 136, 111192
Sigma-1 receptor modulation by fluvoxamine ameliorates valproic acid-induced autistic behavior in rats: Involvement of chronic ER stress modulation, enhanced autophagy and M1/M2 microglia polarization
- 5 November 2024
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 136, 111192
Sigma-1 receptor modulation by fluvoxamine ameliorates valproic acid-induced autistic behavior in rats: Involvement of chronic ER stress modulation, enhanced autophagy and M1/M2 microglia polarization
- 1 January 2023
- Vol. 27 (16) , 7607-7619
A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin
OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver metabolic disease affecting millions globally. This study aimed to assess the safety and efficacy of a high oral loading dose of cholecalciferol supplement on NAFLD patients and to investigate its potential role on serum inflammatory biomarkers. PATIENTS AND METHODS: One hundred patients with NAFLD and type 2 diabetes mellitus were involved in the study. Eligible patients were randomized among two equal groups. Group 1 received the standard conventional therapy in addition to a placebo. Group 2 received the conventional therapy plus cholecalciferol for 4 months. The improvement in the patients' glycaemic control parameters, liver function tests, lipid profile, and serum 25-hydroxy vitamin D at the end of the study was set as a primary outcome. The secondary outcome was the decrease in steatosis grade in the ultrasound and high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha), signal transducer and activator of factor-3 (STAT-3), nitric oxide (NO), malondialdehyde (MDA), and hepassocin serum levels at the end of the study. RESULTS: Group 2 revealed a significant reduction in the serum levels of lipid profile measures, hs-CRP, alanine aminotransferase (ALT), STAT-3, NO, hepassocin, and MDA compared to the baseline and group 1 results. Whereas group 1 did not show these significant changes. Both groups observed no significant changes in glycemic index, TNF-alpha, aspartate aminotransferase (AST), and albumin levels. CONCLUSIONS: Cholecalciferol is recommended as additional therapy to modulate lipid peroxidation and systemic inflammation alongside other NAFLD therapies.
- 1 January 2023
- Vol. 27 (16) , 7607-7619
A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin
OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver metabolic disease affecting millions globally. This study aimed to assess the safety and efficacy of a high oral loading dose of cholecalciferol supplement on NAFLD patients and to investigate its potential role on serum inflammatory biomarkers. PATIENTS AND METHODS: One hundred patients with NAFLD and type 2 diabetes mellitus were involved in the study. Eligible patients were randomized among two equal groups. Group 1 received the standard conventional therapy in addition to a placebo. Group 2 received the conventional therapy plus cholecalciferol for 4 months. The improvement in the patients' glycaemic control parameters, liver function tests, lipid profile, and serum 25-hydroxy vitamin D at the end of the study was set as a primary outcome. The secondary outcome was the decrease in steatosis grade in the ultrasound and high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha), signal transducer and activator of factor-3 (STAT-3), nitric oxide (NO), malondialdehyde (MDA), and hepassocin serum levels at the end of the study. RESULTS: Group 2 revealed a significant reduction in the serum levels of lipid profile measures, hs-CRP, alanine aminotransferase (ALT), STAT-3, NO, hepassocin, and MDA compared to the baseline and group 1 results. Whereas group 1 did not show these significant changes. Both groups observed no significant changes in glycemic index, TNF-alpha, aspartate aminotransferase (AST), and albumin levels. CONCLUSIONS: Cholecalciferol is recommended as additional therapy to modulate lipid peroxidation and systemic inflammation alongside other NAFLD therapies.
- 1 April 2022
- Published by Egyptian Knowledge Bank in Records of Pharmaceutical and Biomedical Sciences
- Vol. 6 (3) , 28-33
Mechanisms of Cadmium-Induced Testicular Damage
Testicular damage is one of the deleterious effects of cadmium (Cd) toxicity. Cadmium is a serious contaminant to the environment that causes severe damage to a variety of tissues and organs including the liver, kidney, and testes. Moreover, cadmium compounds are classified as carcinogenic substances in humans. Acute and chronic cadmium intoxication results in the formation of reactive oxygen species (ROS), attenuation of anti-oxidant enzyme activity and inducing oxidative stress. In addition, inflammation is induced by cadmium toxicity. So, both oxidative stress and inflammation play an important role in the pathogenesis of testicular damage under cadmium exposure. Oxidative stress is triggered by reactive oxygen species (ROS) and an imbalance between ROS and antioxidant enzymes activities. oxidative stress activates the NF-κB signaling pathway, which controls several genes implicated in inflammatory responses such as TNF-α and iNOS. Cd can pass through the blood-testes barrier, causing changes in the hypothalamic-pituitary-testicular axis and DNA damage The harmful effect of cadmium on testes is known to be germ cell degeneration and impairment of testicular steroidogenesis due to damage in testicular Leydig cells.
- 1 April 2022
- Published by Egyptian Knowledge Bank in Records of Pharmaceutical and Biomedical Sciences
- Vol. 6 (3) , 28-33
Mechanisms of Cadmium-Induced Testicular Damage
Testicular damage is one of the deleterious effects of cadmium (Cd) toxicity. Cadmium is a serious contaminant to the environment that causes severe damage to a variety of tissues and organs including the liver, kidney, and testes. Moreover, cadmium compounds are classified as carcinogenic substances in humans. Acute and chronic cadmium intoxication results in the formation of reactive oxygen species (ROS), attenuation of anti-oxidant enzyme activity and inducing oxidative stress. In addition, inflammation is induced by cadmium toxicity. So, both oxidative stress and inflammation play an important role in the pathogenesis of testicular damage under cadmium exposure. Oxidative stress is triggered by reactive oxygen species (ROS) and an imbalance between ROS and antioxidant enzymes activities. oxidative stress activates the NF-κB signaling pathway, which controls several genes implicated in inflammatory responses such as TNF-α and iNOS. Cd can pass through the blood-testes barrier, causing changes in the hypothalamic-pituitary-testicular axis and DNA damage The harmful effect of cadmium on testes is known to be germ cell degeneration and impairment of testicular steroidogenesis due to damage in testicular Leydig cells.